The Epidemiology of Multidrug-Resistant Pathogens in Hematopoietic Stem Cell Transplantation (HSCT) Patients: A Five-Year Retrospective Study at a Cancer Center
Pathogens · 2026-06-28 · 15 (7) · 684
DOI: 10.3390/pathogens15070684 ↗At a glance
Journal article in Pathogens, published online on 2026-06-28. Written by Sawsan Mubarak and 4 co-authors. Institution: Infection Control Program, King Hussein Cancer Center, Amman 11941, Jordan. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Drug Resistance, Multiple, Bacterial, Bacterial Infections, Bacteria. 21 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Multidrug-resistant (MDR) pathogens present a significant threat to hematopoietic stem cell transplant (HSCT) recipients; despite their critical implications, regional data on their infection patterns remain scarce. This study aimed to characterize the incidence, pathogen and antimicrobial resistance distribution of clinically confirmed bacterial infections among HSCT recipients. A retrospective analysis was conducted at King Hussein Cancer Center, Jordan (2018–2022). MDR pathogens were defined per CDC criteria. During the study period, 1157 HSCT procedures were performed. A total of 327 patients developed clinically documented bacterial infections, yielding an overall cumulative incidence of 28.3%, with a higher burden in the pediatric cohort (34.7%), including exclusive identification of Klebsiella oxytoca in pediatrics (2.3%). Gram-negative bacteria dominated, with Escherichia coli (50.5%) and Klebsiella pneumoniae (22.0%) being most common. Extended-spectrum beta-lactamase (ESBL) production was the dominant resistance mechanism (71.3%), followed by carbapenem-resistant Enterobacteriaceae (CRE; 14.1%), methicillin-resistant Staphylococcus aureus (MRSA; 8.6%), and carbapenem-resistant Pseudomonas aeruginosa (CRPA; 7.0%). The urogenital (39.1%) and bloodstream (31.2%) were the most infected sites. Significant site-specific associations were noted for ESBL production, MDR-Acinetobacter baumannii (p < 0.001) and MRSA (p = 0.007). Temporal analysis revealed a convergent MDR peak in 2021. Our findings offer critical insights into MDR pathogen incidence in HSCT recipients in the Middle East, informing improved infection management and intensified antimicrobial stewardship in this high-risk population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Infection Control Program, King Hussein Cancer Center, Amman 11941, Jordan.
- Department of Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
ORCID profiles: Yara K Edor, Hadeel AlGhawrie
Cite
APA
Mubarak, S., Jarrah, J., Edor, Y. K., Khresat, O., & AlGhawrie, H. (2026). The Epidemiology of Multidrug-Resistant Pathogens in Hematopoietic Stem Cell Transplantation (HSCT) Patients: A Five-Year Retrospective Study at a Cancer Center. Pathogens, 15(7), 684. https://doi.org/10.3390/pathogens15070684
Vancouver
Mubarak S, Jarrah J, Edor YK, Khresat O, AlGhawrie H. The Epidemiology of Multidrug-Resistant Pathogens in Hematopoietic Stem Cell Transplantation (HSCT) Patients: A Five-Year Retrospective Study at a Cancer Center. Pathogens. 2026;15(7):684. doi:10.3390/pathogens15070684
BibTeX
@article{Mubarak2026,
author = {Mubarak, Sawsan and Jarrah, Joud and Edor, Yara K and Khresat, Omar and AlGhawrie, Hadeel},
title = {The Epidemiology of Multidrug-Resistant Pathogens in Hematopoietic Stem Cell Transplantation (HSCT) Patients: A Five-Year Retrospective Study at a Cancer Center},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {7},
pages = {684},
doi = {10.3390/pathogens15070684}
}
EUVIMED